CN1733242A - Medicine for curing qi deficiency induced thoracic obstruction (coronary heart disease) and technique for preparing the same - Google Patents
Medicine for curing qi deficiency induced thoracic obstruction (coronary heart disease) and technique for preparing the same Download PDFInfo
- Publication number
- CN1733242A CN1733242A CN 200510097971 CN200510097971A CN1733242A CN 1733242 A CN1733242 A CN 1733242A CN 200510097971 CN200510097971 CN 200510097971 CN 200510097971 A CN200510097971 A CN 200510097971A CN 1733242 A CN1733242 A CN 1733242A
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- heart disease
- coronary heart
- thoracic obstruction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 54
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 41
- 230000007812 deficiency Effects 0.000 title claims abstract description 15
- 210000000115 thoracic cavity Anatomy 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title abstract description 7
- 229940079593 drug Drugs 0.000 title description 16
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 21
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 21
- 235000015511 Liquidambar orientalis Nutrition 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 239000008280 blood Substances 0.000 claims description 39
- 210000004369 blood Anatomy 0.000 claims description 38
- 241000208340 Araliaceae Species 0.000 claims description 19
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 19
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 19
- 235000008434 ginseng Nutrition 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 15
- 241000628997 Flos Species 0.000 claims description 14
- 241000736148 Styrax Species 0.000 claims description 13
- 239000004870 Styrax Substances 0.000 claims description 13
- 235000000126 Styrax benzoin Nutrition 0.000 claims description 13
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 238000005516 engineering process Methods 0.000 claims description 6
- 241000411851 herbal medicine Species 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000009495 sugar coating Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 241000893513 Liquidambar orientalis Species 0.000 abstract 1
- 241000756042 Polygonatum Species 0.000 abstract 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 239000001886 liquidambar orientalis Substances 0.000 abstract 1
- 210000003296 saliva Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 25
- 208000002193 Pain Diseases 0.000 description 15
- 230000017531 blood circulation Effects 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 230000001737 promoting effect Effects 0.000 description 14
- 206010002383 Angina Pectoris Diseases 0.000 description 12
- 208000011580 syndromic disease Diseases 0.000 description 12
- 210000002216 heart Anatomy 0.000 description 11
- 206010002660 Anoxia Diseases 0.000 description 6
- 241000976983 Anoxia Species 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 230000007953 anoxia Effects 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000031225 myocardial ischemia Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000008899 fufang danshen Substances 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 231100000862 numbness Toxicity 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 3
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 3
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 206010060965 Arterial stenosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940071462 oralone Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- PRYXPGFZVGZNBL-ADLFWFRXSA-N salviol Chemical compound CC(C)c1cc2CC[C@H]3C(C)(C)C[C@H](O)C[C@]3(C)c2cc1O PRYXPGFZVGZNBL-ADLFWFRXSA-N 0.000 description 1
- AJSGWTLZEUBGFV-UHFFFAOYSA-N salviol Natural products CC(C)c1cc2CCC3C(CC(O)CC3(C)C)c2cc1O AJSGWTLZEUBGFV-UHFFFAOYSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine for curing qi deficiency induced thoracic obstruction (coronary heart disease) and technique for preparation, wherein the medicine is prepared from the following Chinese medicinal herbs: Ligusticum wallichii, notoginseng, gen-seng, root of red rooted saliva, radix paeoniae rubrathe, safflower, fragrant solomonseal rhizome, liquidambar orientalis mill, Ligusticum wallichii, boneol.
Description
Technical field
The present invention relates to a kind of is the Chinese patent medicine and preparation method thereof of the treatment thoracic obstruction (coronary heart disease) made of raw material with Chinese herbal medicine.
Technical background
The traditional Chinese medical science claims the thoracic obstruction, the doctor trained in Western medicine cardiopathia that wins, it is one of person in middle and old age's common frdquently encountered disease, at present according to epidemiology statistics, the trend that rejuvenation is arranged, coronary heart disease motherland medical science is thought: pathogenesis is the loss owing to internal organs such as heart kidney,spleen,livers, and the imbalance of " seven emotions " " six desire " causes " flaccidity of the heart-yang " " stagnation of phlegm heart arteries and veins " " qi depression to blood stasis " " blood stasis due to qi deficiency " " stagnation of heart-blood " " venation is obstructed " stagnation of QI and blood may bring about pain.Modern medicine thinks that coronary heart disease is because of coronary atherosclerosis, and thrombosis causes coronary stricture, blood supply insufficiency, myocardial ischemia, anoxybiotic a kind of heart disease.
At present clinically the expectant treatment method is generally adopted in the treatment of this disease.Be the Chinese medicine and western medicine oral medication, adopt the western medicine side effect big, should not long clothes, cure the symptoms, not the disease, because primary disease belongs to chronic disease, meet the easy acute outbreak of various stimulations, threat to life.
Summary of the invention:
Purpose of the present invention just provides a kind of pure Chinese medicinal preparation that therapeutic effect is good and side effect is little that is used for the treatment of the thoracic obstruction (coronary heart disease) and preparation method thereof.
The Chinese patent medicine of the treatment thoracic obstruction (coronary heart disease) that the present invention proposes mainly contains the Chinese herbal medicine composition of weight portion down:
Radix Salviae Miltiorrhizae 200-250g Radix Paeoniae Rubra 100-125g Rhizoma Chuanxiong 100-125g
Flos Carthami 100-125g Rhizoma Polygonati Odorati 100-125g Radix Notoginseng 40-50g
Radix Ginseng 20-25g Styrax 8-10g Borneolum Syntheticum 2-2.5g
The method that above-mentioned each group is equipped with into Chinese patent medicine preparation respectively:
(1) Rhizoma Chuanxiong, Radix Notoginseng, Radix Ginseng powder are broken into fine powder, cross 100 mesh sieves;
(2) Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Flos Carthami, Rhizoma Polygonati Odorati are decocted with water secondary, each 2 hours, merging filtrate, concentrating under reduced pressure is the thick paste of 1.35-1.45 (40-50 ℃) in 0.06-0.08MPa, 50-60 ℃ condition down to relative density, and Styrax is dissolved in the thick paste;
(3) with Rhizoma Chuanxiong, Radix Notoginseng, Radix Ginseng fine powder and above-mentioned thick paste mixing, make granule, dried making an uproar;
(4) Borneolum Syntheticum is blended into mixing in the granule, suppresses sugar coating in blocks, or granule is promptly encapsulated.
Good effect of the present invention is as follows:
Radix Salviae Miltiorrhizae in the medicine of the present invention: this product has activating blood and removing stasis, and removing heat from blood disappears and acts on bitterly.So be the product of removing heat from blood and promoting blood circulation promoting blood circulation.Because of containing Radix Salviae Miltiorrhizae trunk, saivianic acid A fat, salviol etc., to the microcirculation improvement aspect, improve the anoxia enduring power of human body, accelerate the microcirculation velocity of blood flow, the adjustment rhythm of the heart etc. all has better action.
Radix Paeoniae Rubra: the dispelling row band that becomes silted up, again can alleviating pain, especially with heat in blood stasis person use for good.With treatment angina pectoris, one of more satisfactory medicine.
Rhizoma Chuanxiong: activating blood and removing stasis is arranged, the promoting the circulation of QI to relieve pain effect.This product contains volatile oil, alkaloid, and the phenol alkaloid, lactone, organic acid etc., to excited medullary respiratory center, vasomotor center can directly be expanded peripheral vessels and impel coronary artery blood flow.
Flos Carthami: promoting blood circulation to restore menstrual flow, reducing swelling and alleviating pain.Common drug for promoting blood circulation and stopping pain.
Radix Notoginseng: the hemostasis of becoming silted up of loosing, reducing swelling and alleviating pain.Single in recent years according to reports Radix Notoginseng powder of using, treatment coronary heart disease angina cordis is obtained curative effect preferably.
Rhizoma Polygonati Odorati: nourishing YIN and moistening the lung, the nourishing the stomach of promoting the production of body fluid has people's list to be decocted in water for oral dose with Rhizoma Polygonati Odorati in recent years, and to coronary atherosclerotic heart disease, heart failure etc. are all obtained effect preferably.
Radix Ginseng: big QI invigorating, invigorating the spleen to benefit the lung, promoting the production of body fluid to quench thirst, calming the nerves increases intelligence.
Borneolum Syntheticum: the refreshment of having one's ideas straightened out, clearing away heat to alleviate pain.The merit that this product has fragrance to walk to scurry.
Styrax: have one's ideas straightened out and ward off dirty, pain relieving.The hot temperature of loosing of this product is logical, and fragrance is warded off evil, and the effect of having one's ideas straightened out is arranged.
In sum, we are with Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Flos Carthami, Radix Notoginseng, Rhizoma Chuanxiong activating blood and removing stasis, and promoting the circulation of QI to relieve pain can lead to heart arteries and veins, dispelling become silted up to hinder, and are suitable for congestion numbness to hinder obstruction of qi in the chest and cardialgia disease due to the heart arteries and veins especially.
The Radix Ginseng invigorating primordial QI, the beneficial motive, qi as the commander of blood, " blood circulation depending on qi flow " compatibility activating blood circulation to dissipate blood stasis medicine comes Shi Zhigong to reach " the logical benefit ".
Styrax: Borneolum Syntheticum fragrance is walked to scurry, and the through sick institute of all medicines is drawn in the silt pain relieving of loosing.To strengthen the effect of our QI invigorating silt.
The Rhizoma Polygonati Odorati reinforcing stomach reg fluid is to make the fraud of hot fragrant circulation of qi promoting impairment of YIN.
In the medicine of the present invention, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra blood circulation promoting and blood stasis dispelling, clearing away heat to alleviate pain; Radix Notoginseng, Flos Carthami promoting blood circulation to remove blood stasis, coronary circulation-promoting pain-relieving; Rhizoma Chuanxiong blood circulation promoting and blood stasis dispelling in the compatibility, promoting the circulation of QI to relieve pain, " the capable then blood of gas is capable ", thoracic obstruction angor to due to the blood stasis numbness resistance heart arteries and veins has better curative effect, the Radix Ginseng invigorating primordial QI, the benefit motive, qi as the commander of blood, " blood circulation depending on qi flow " compatibility activating blood and removing stasis drug is to reach " the logical benefit " double effect of executing; Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Radix Notoginseng, Flos Carthami, Rhizoma Chuanxiong compatibility Radix Ginseng can strengthen the effect that blood stasis dispelling is promoted blood circulation, dirty, turbid, the refreshment pain relieving of change that Styrax, Borneolum Syntheticum are had one's ideas straightened out, warded off, but the Rhizoma Polygonati Odorati heat clearing away and restlessness relieving that above medicine is equipped with YIN nourishing, promotes the production of body fluid.
In sum, with motherland's medical angle, all kinds to the Chinese medical discrimination obstruction of qi in the chest and cardialgia, the resistance of breast sun numbness, deficiency of both QI and YIN etc., though clinical manifestation is different, its pathologic basis is identical, i.e. " blood stasis due to qi deficiency; stricture of artery, blood supply insufficiency ", the quiet main performance of medicine coronary disease of the present invention is a benefiting QI for activating blood circulation, warm Tonghua stasis of blood.
With the thoracic obstruction that Drug therapy blood stasis due to qi deficiency of the present invention causes, chest pain, the cardiopalmus of breathing hard and coronary heart disease see above-mentioned symptom person, oral one time 4 (grain), 3 times on the one, be 30 the course of treatment, can take continuously, clinical observation 317 examples, total effective rate 94%, electrocardiogram improves 74.19%.
Medicine of the present invention be deficiency in origin and excess in superficiality the thoracic obstruction (coronary heart disease) and cube, unique refine of writing out a prescription, the clinical obstruction of qi in the chest and cardialgia that can treat congestion numbness resistance heart arteries and veins can prevent the acute attack of coronary heart disease again, long clothes have no adverse reaction, dosage is little, determined curative effect.
Medicine coronary disease still acute toxicity testing of the present invention: the main acute toxic reaction of investigating medicine coronary disease still of the present invention to mice of this test, the result shows that medicine coronary disease still of the present invention gives the mouse stomach administration to be higher than 160 times of human dosage, observe and do not see dead mouse on the 7th, its activity, diet are normal.Result and conclusion: medicine coronary disease still of the present invention is to be higher than 160 times of mouse stomach administrations of people's consumption, and activity at that time reduces to some extent behind the filling stomach, movable recovery in afternoon on the same day.Observe and do not see dead mouse on the 7th, its activity, diet are normal.
Medicine of the present invention shows through rat long term toxicity test result, give the rat continuous oral longer course of treatment (90d) with medicine coronary disease still heavy dose of the present invention (12.5 times, 25 times and 50 times of amounts of adult's dosage), growth promoter (body weight gain), hemopoietic function, liver function and renal function to rat do not have the overt toxicity reaction, and organs such as the rat heart, liver, lung kidney, brain are also found no toxicity damage sexually transmitted disease (STD) reason change in organization.Show very low, the safety of the longer course of treatment and large dose oral administration medicine coronary disease of the present invention still toxicity.
Medicine coronary disease still of the present invention shows the experimental result of mice normal pressure anoxia enduring death time influence: medicine coronary disease still group of the present invention and blank group relatively have significant difference, and high, medium and low three dosage groups of medicine coronary disease still of the present invention and positive drug compound Salviae Miltiorrhizae group be the time-to-live (p＜0.01) of energy significant prolongation normal pressure anoxia enduring animal all.Conclusion: medicine coronary disease still of the present invention can obviously prolong the anoxia in mice following time-to-live of condition.
Medicine coronary disease still of the present invention causes the observation of acute myocardial ischemia antagonism to pituitrin, test has been investigated medicine coronary disease still of the present invention and has been caused the antagonism of rabbit acute myocardial ischemia to the influence of mice normal pressure anoxia enduring death time and to pituitrin, and the result shows: medicine coronary disease still of the present invention can obviously prolong the anoxia in mice following time-to-live of condition; The myocardial ischemia that pituitrin is caused has certain antagonism, proves that medicine coronary disease still of the present invention has the certain protection effect to expeirmental myocardial ischemia.
Clinical data
1, diagnostic criteria:
(1) Western medicine diagnose standard (with reference to International Society of Cardiology and association and World Health Organization's clinical name standardization associating special topic group report " name of ischemic heart desease and diagnosis shelves are accurate ") is divided into fatigue angina pectoris, spontaneous angina pectoris.
(2) tcm syndrome diagnostic criteria is (with reference to GB " tcm clinical practice diagnosis and treatment term syndrome part " 1997-03-04 issue and high medical college teaching material " Chinese Internal Medicine " Science and Technology of Shanghai publishing house, in October, 1985, front page) is divided into heart blood silt, syndrome of qi stagnation and blood stasis, syndrome of phlegm blocking heart vessel, YIN-cold stagnate card, syndrome of deficiency of both qi and yin.
2, case:
(1) accepts patients with coronary heart disease 240 examples altogether for medical treatment, divide into groups, take coronary disease still 142 examples, be the treatment group by the random packet method; Take FUFANG DANSHEN PIAN 98 examples and be matched group.
Treatment group male 111 examples, women's 31 examples, cadre's 73 examples, workman's 50 examples, peasant's 12 examples, other 7 examples;
Matched group male 70 examples, women's 28 examples, cadre's 40 examples, workman's 33 examples, peasant's 15 examples, other 10 examples.
Two groups of age recklings 37 years old, maximum 74 years old, average 47 years old.
(2) state of an illness scalar quantization: 142 examples are organized in treatment, its mild or moderate 46 examples, moderate 73 examples, severe 23 examples;
Matched group 98 examples, its mild or moderate 39 examples, moderate 48 examples, severe 11 examples.
Treatment and observational technique
1, medicament sources: medicine coronary disease still of the present invention is produced by Baoding Chinese Traditional Medicine Co., Ltd., and FUFANG DANSHEN PIAN is produced by Baoding Chinese Traditional Medicine Co., Ltd..
2, the dosage and the course of treatment: 4 of medicine coronary disease stills of the present invention oral a time, 3 times on the one, serveing on 1 month is a course of treatment;
3 of FUFANG DANSHEN PIAN oral a time, 3 times on the one, serveing on 1 month is a course of treatment.
Period in a medicine is withdrawn other coronary heart disease is treated the influential Chinese and western drugs in suburb except that acute attack.
3, observational technique: all observe case, all fill in patient medical history in detail and observe registration form.Before the test two groups of patients are all done relevant physico-chemical examination.Health giving quality is observed, and related symptoms, sign should write down weekly 1 time.Respectively carry out health giving quality statistical analysis after finishing the course of treatment.
4, follow up a case by regular visits to registration: follow up a case by regular visits to the seasonable row of the effective case of part the test back, comprises angina pectoris and clinical symptoms, the variation of electrocardiogram and physico-chemical examination.Formulate concrete scheme, conscientiously record is estimated Follow-up results according to criterion of therapeutical effect.
Efficacy determination
According to tcm syndrome curative effect determinate standard and curative effect of disease criterion.
Produce effects: clinical symptoms, sign is obviously improved, and the syndrome integration reduces 〉=70%.Cardinal symptoms such as angina pectoris disappear or reach the produce effects standard, and electrocardiogram returns to normal ECG or reaches roughly normal.
Effectively: clinical symptoms, sign all take a favorable turn, and the syndrome integration reduces 〉=30%.Cardinal symptoms such as angina pectoris alleviate or reach effective standard, and electrocardiogram improves effective standard that reaches.
Invalid: clinical symptoms, sign do not have obvious improvement, even increase the weight of, and the syndrome integration reduces＜30%.Cardinal symptoms such as angina pectoris do not have improvement, and electrocardiogram is preceding identical with treatment substantially.
Increase the weight of: clinical symptoms, sign all have and increase the weight of syndrome integration＜0.Cardinal symptom such as angina pectoris and electrocardiogram increase the weight of before the test.
Therapeutic outcome
| The treatment group | Produce effects 84 (59.2%) | Effective 50 (35.2%) | Invalid 8 (5.6%) | Effective percentage 94.4% |
| Matched group | 52(53.1％) | 31(31.6％) | 15(15.3％) | 84.7％ |
The dialectical observation table of treatment group TCM Syndrome Type
| Typing | The example number | Produce effects | Effectively | Invalid | Effective percentage % |
| Blood stasis due to qi deficiency | 78 | 47(60.3％) | 27(34.6％) | 4(5.1％) | 94.9％ |
| Qi depression to blood stasis | 64 | 37(57.8％) | 23(35.9％) | 4(6.3％) | 93.7％ |
| Add up to | 142 | 84(59.2％) | 50(35.2％) | 8(5.6％) | 94.4％ |
The dialectical observation table of matched group TCM Syndrome Type
| Typing | The example number | Produce effects | Effectively | Invalid | Effective percentage % |
| Blood stasis due to qi deficiency | 55 | 2749.1％) | 19(34.5％) | 9(16.4％) | 83.6％ |
| Qi depression to blood stasis | 43 | 25(58.1％) | 12(27.9％) | 6(14％) | 86％ |
| Add up to | 98 | 52(53.1％) | 31(31.6％) | 15(15.3％) | 84.7％ |
The result shows: to sum up state the observation table, medicine coronary disease still total effective rate of the present invention is higher than FUFANG DANSHEN PIAN.
One, conclusion
1, coronary heart disease is primary symptom with suffocating pain over the chest, the cardiopalmus of breathing hard, and belongs to motherland's medical science thoracic obstruction category, clinically reaches that the formula stasis of blood is closed, breast arteries and veins stasis of blood resistance person sees more.Medicine coronary disease still of the present invention has the effect of blood circulation promoting and blood stasis dispelling, supplementing qi and invigorating vasculum.The thoracic obstruction, chest pain, the cardiopalmus of breathing hard that Qi deficiency blood stasis type, qi stagnation and blood stasis type coronary heart disease are caused have therapeutical effect preferably, and through 142 routine patient's clinical verifications, total effective rate reaches 94.4%, according to following up a case by regular visits to record, most of patient's clinical symptoms is improved, favourable prognosis.
2, there is case in observation post, and all cases have been carried out blood, urine, conventional hepatic and renal function inspection, and no abnormal change does not have any untoward reaction.
3, to the case of failing to respond to any medical treatment, adopt composite treatment, symptom also be improved significantly.
4, medicine coronary disease still prescription compatibility of medicines of the present invention is rigorous, determined curative effect, and reliable and stable, to the deficiency of vital energy, the qi depression to blood stasis patients with coronary heart disease is evident in efficacy.
Model case 1
Dong Wenqin, the woman, 65 years old, the doctor, the thoracic obstruction of qi depression to blood stasis, chest pain is uncomfortable in chest before taking medicine, fullness and distention in the chest and hypochondrium, cardiopalmus, the words purple secretly has petechiae, hesitant pulse, need obey nitroglycerin during chest pain, can alleviate, and the electrocardio diagram: II, III, AVF lead abnormal Q S ripple; T II IIIAVF is inverted, and is crown T form; TV5 is low flat, and three months metathorax alleviation of pain of taking medicine gently are dull pain, all the other transference cures; Nitroglycerin is withdrawn, and electrocardiogram improves, and III leads and the R ripple occurs; The QRS wave group transfers the QR type to by the QS type, and T II is upright, and the T III AVF degree of depth also shoals, and T TV5 is upright.
Model case 2:
Liu Changshun, man, 38 years old, electrician, the thoracic obstruction of blood stagnancy due to deficiency of QI, chest pain is uncomfortable in chest before taking medicine, and shortness of breath and palpitation is refreshing tired weak, complexion is dim, and the purple ecchymosis is arranged on the tongue, and weak pulse is and puckery, and electrocardio diagram T II III AVF is low flat, be inverted, STV5 horizontal type decline 0.05mv, take medicine the back except that feel slightly uncomfortable in chest, all the other transference cures, still for being inverted, all the other all recover normally for electrocardiogram T, III, sleep, appetite, spirit, muscle power are clearly better before all taking medicine.
Model case 3
Zhao Lanting, the man, 50 years old, the cadre, the thoracic obstruction of blood stagnancy due to deficiency of QI, the preceding chest pain of taking medicine, shortness of breath and palpitation, complexion is purple dark, the light red tongue purple, weak pulse and puckery has knot generation, and electrocardio diagram: TAVF is low flat; T III two-phase; On AVR, V3 and V5 lead premature beat is arranged, after taking medicine, the chest pain number of times reduces, and intermittent pulse disappears, and it is upright that electrocardiogram TAVF becomes, and premature beat disappears.
The specific embodiment
Embodiment 1:
Adopt following ratio of weight and number Chinese herbal medicine composition:
Radix Salviae Miltiorrhizae 215 Radix Paeoniae Rubra 100 Rhizoma Chuanxiongs 115 Flos Carthamis 110 Rhizoma Polygonati Odorati 110
Radix Notoginseng 40 Radix Ginsengs 22 Styrax 9 Borneolum Syntheticums 2.2
The technology of preparation medicine of the present invention is as follows:
(1) Rhizoma Chuanxiong, Radix Notoginseng, Radix Ginseng powder are broken into fine powder, cross 80 mesh sieves;
(2) Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Flos Carthami, Rhizoma Polygonati Odorati are decocted with water secondary, each 2 hours, merging filtrate under 0.06MPa, 50 ℃ of conditions, was evaporated to the relative density that records and is 1.40 thick paste under 50 ℃ of temperature, Styrax is dissolved in the thick paste;
(3) with Rhizoma Chuanxiong, Radix Notoginseng, Radix Ginseng fine powder and above-mentioned thick paste mixing, make granule, dried making an uproar:
(4) Borneolum Syntheticum is blended into mixing in the granule, compacting is in blocks, sugar coating, or granule is promptly encapsulated.
Embodiment 2:
The present invention adopts following ratio of weight and number Chinese herbal medicine composition:
Radix Salviae Miltiorrhizae 200 Radix Paeoniae Rubra 125 Rhizoma Chuanxiongs 115 Flos Carthamis 125 Rhizoma Polygonati Odorati 100
Radix Notoginseng 45 Radix Ginsengs 25 Styrax 8 Borneolum Syntheticums 2
The technology of preparation medicine of the present invention is as follows:
(1) Rhizoma Chuanxiong, Radix Notoginseng, Radix Ginseng powder are broken into fine powder, cross 90 mesh sieves;
(2) Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Flos Carthami, Rhizoma Polygonati Odorati are decocted with water secondary, each 3 hours, merging filtrate under 0.08MPa, 60 ℃ of conditions, was evaporated to the relative density that records and is 1.35 thick paste under 45 ℃ of temperature, Styrax is dissolved in the thick paste;
(3) with Rhizoma Chuanxiong, Radix Notoginseng, Radix Ginseng fine powder and above-mentioned thick paste mixing, make granule, dried making an uproar;
(4) Borneolum Syntheticum is blended into mixing in the granule, compacting is in blocks, sugar coating, or granule is promptly encapsulated.
Embodiment 3:
Adopt following ratio of weight and number Chinese herbal medicine composition:
Radix Salviae Miltiorrhizae 250 Radix Paeoniae Rubra 110 Rhizoma Chuanxiongs 100 Flos Carthamis 100 Rhizoma Polygonati Odorati 125
Radix Notoginseng 50 Radix Ginsengs 20 Styrax 10 Borneolum Syntheticums 2.5
The technology of preparation medicine of the present invention is as follows:
(1) Rhizoma Chuanxiong, Radix Notoginseng, Radix Ginseng powder are broken into fine powder, cross 100 mesh sieves;
(2) Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Flos Carthami, Rhizoma Polygonati Odorati are decocted with water secondary, each 2.5 hours, merging filtrate under 0.07MPa, 55 ℃ of conditions, was evaporated to the relative density that records and is 1.45 thick paste under 40 ℃ of temperature, Styrax is dissolved in the thick paste;
(3) with Rhizoma Chuanxiong, Radix Notoginseng, Radix Ginseng fine powder and above-mentioned thick paste mixing, make granule, dried making an uproar;
(4) Borneolum Syntheticum is blended into mixing in the granule, compacting is in blocks, sugar coating, or granule is promptly encapsulated.
Claims (2)
1, the medicine of a kind of treatment blood stasis-type thoracic obstruction caused by qi deficiency (coronary heart disease) is characterized in that adopting following ratio of weight and number Chinese herbal medicine composition:
Radix Salviae Miltiorrhizae 200-250 Radix Paeoniae Rubra 100-125 Rhizoma Chuanxiong 100-125
Flos Carthami 100-125 Rhizoma Polygonati Odorati 100-125 Radix Notoginseng 40-50
Radix Ginseng 20-25 Styrax 8-10 Borneolum Syntheticum 2-2.5
2, the technology of the medicine of preparation treatment blood stasis-type thoracic obstruction caused by qi deficiency (coronary heart disease) comprises the following steps:
(1) Rhizoma Chuanxiong, Radix Notoginseng, Radix Ginseng powder are broken into fine powder, cross the 80-100 mesh sieve;
(2) Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Flos Carthami, Rhizoma Polygonati Odorati are decocted with water secondary, each 2-3 hour, merging filtrate was under 0.06-0.08MPa, 50-60 ℃ condition, being evaporated to the relative density that records under 40-50 ℃ of temperature is the thick paste of 1.35-1.45, and Styrax is dissolved in the thick paste;
(3) with Rhizoma Chuanxiong, Radix Notoginseng, Radix Ginseng fine powder and above-mentioned thick paste mixing, make granule, drying;
(4) Borneolum Syntheticum is blended into mixing in the granule, suppresses sugar coating in blocks or granule is promptly encapsulated.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100979713A CN1306951C (en) | 2005-09-02 | 2005-09-02 | Medicine for curing qi deficiency induced thoracic obstruction (coronary heart disease) and technique for preparing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100979713A CN1306951C (en) | 2005-09-02 | 2005-09-02 | Medicine for curing qi deficiency induced thoracic obstruction (coronary heart disease) and technique for preparing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1733242A true CN1733242A (en) | 2006-02-15 |
| CN1306951C CN1306951C (en) | 2007-03-28 |
Family
ID=36075997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100979713A Active CN1306951C (en) | 2005-09-02 | 2005-09-02 | Medicine for curing qi deficiency induced thoracic obstruction (coronary heart disease) and technique for preparing the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1306951C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101084995B (en) * | 2006-06-08 | 2011-10-05 | 天津天士力制药股份有限公司 | Medicinal composition containing red sage root and storax, preparation method and preparation |
| CN104288505A (en) * | 2014-09-10 | 2015-01-21 | 秦永双 | Traditional Chinese medicine preparation for treating qi deficiency and blood stasis type coronary heart disease and nursing method |
| CN106728877A (en) * | 2017-02-15 | 2017-05-31 | 南京市第医院 | It is a kind of to treat medicament of coronary disease and angina pectoris and preparation method thereof |
| CN108096433A (en) * | 2017-12-31 | 2018-06-01 | 何江 | Treat Chinese medicinal capsule of Senile Coronary Heart Disease syndrome of blood stasis due to qi deficiency and preparation method thereof |
| CN110339326A (en) * | 2019-08-29 | 2019-10-18 | 朱江 | A kind of logical heart ball of stilbene deer |
| CN115089628A (en) * | 2022-07-08 | 2022-09-23 | 北京康恩泰生物医药有限公司 | Traditional Chinese medicine granule for treating coronary heart disease |
-
2005
- 2005-09-02 CN CNB2005100979713A patent/CN1306951C/en active Active
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101084995B (en) * | 2006-06-08 | 2011-10-05 | 天津天士力制药股份有限公司 | Medicinal composition containing red sage root and storax, preparation method and preparation |
| CN104288505A (en) * | 2014-09-10 | 2015-01-21 | 秦永双 | Traditional Chinese medicine preparation for treating qi deficiency and blood stasis type coronary heart disease and nursing method |
| CN106728877A (en) * | 2017-02-15 | 2017-05-31 | 南京市第医院 | It is a kind of to treat medicament of coronary disease and angina pectoris and preparation method thereof |
| CN108096433A (en) * | 2017-12-31 | 2018-06-01 | 何江 | Treat Chinese medicinal capsule of Senile Coronary Heart Disease syndrome of blood stasis due to qi deficiency and preparation method thereof |
| CN110339326A (en) * | 2019-08-29 | 2019-10-18 | 朱江 | A kind of logical heart ball of stilbene deer |
| CN115089628A (en) * | 2022-07-08 | 2022-09-23 | 北京康恩泰生物医药有限公司 | Traditional Chinese medicine granule for treating coronary heart disease |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1306951C (en) | 2007-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100382839C (en) | Chinese-medicinal composition for treating coronary heart disease | |
| CN1857618A (en) | Chinese medicine preparation for reducing sugar | |
| CN1240416C (en) | Medicine for curing hypertension and its preparation method | |
| CN1628760A (en) | Traditional Chinese medicinal formulation for treating cardiovascular and cerebrovascular disease | |
| CN101822789B (en) | Hypotensor treating essential hypertension | |
| CN1306951C (en) | Medicine for curing qi deficiency induced thoracic obstruction (coronary heart disease) and technique for preparing the same | |
| CN103393749A (en) | Traditional Chinese medicine for preventing and treating ischemic cardiovascular and cerebrovascular diseases | |
| CN102343049B (en) | Chinese medicinal capsules for treating hypertension due to liver-yang hyperactivity | |
| CN101007159A (en) | Traditional Chinese medicine for preventing and controlling tumor | |
| CN1045892C (en) | Chinese medicine Guanxintong for preventing and curing coronary heart disease and angina pectoris, and producing process thereof | |
| CN102908425A (en) | Medicine for treating heart diseases and thick blood lipid and preparation method of the medicine | |
| CN102048939A (en) | Medicament for treating sinus bradycardia | |
| CN105902853A (en) | Traditional Chinese medicine preparation for preparing hypertension | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN101057945A (en) | Traditional Chinese medicine for treating digestive cancer and its producing method | |
| CN1086586C (en) | Medicine for treating cardiac and cerebral vascular diseases and its preparation | |
| CN1990033A (en) | Drug for treating hypertension, dense blood and arteriosclerosis | |
| CN1247237C (en) | Medicinal composition for treating coronary disease and its preparation and application | |
| CN112206279B (en) | Traditional Chinese medicine composition for treating ventricular arrhythmia and preparation method and application thereof | |
| CN1293971A (en) | Medicine for treating apoplexy and its preparing process | |
| CN111388623B (en) | Traditional Chinese medicine for treating coronary heart disease | |
| CN107737234A (en) | A kind of medicine for preventing and treating diabete peripheral herve pathology | |
| CN105770520A (en) | Medicine preparation used for treating coronary heart disease and application thereof | |
| CN104096112A (en) | Traditional Chinese medicine composition for treating angina pectoris | |
| CN1256963C (en) | Antifatigue medicine and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine for curing qi deficiency induced thoracic obstruction (coronary heart disease) and technique for preparing the same Effective date of registration: 20110705 Granted publication date: 20070328 Pledgee: Anguo branch of China Co truction Bank Corp Pledgor: Baoding Chinese Medicine Preparing Co., Ltd. Registration number: 2011990000254 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20121123 Granted publication date: 20070328 Pledgee: Anguo branch of China Co truction Bank Corp Pledgor: Baoding Chinese Medicine Preparing Co., Ltd. Registration number: 2011990000254 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine for curing qi deficiency induced thoracic obstruction (coronary heart disease) and technique for preparing the same Effective date of registration: 20131210 Granted publication date: 20070328 Pledgee: Bank of Hebei, Limited by Share Ltd, Baoding branch Pledgor: Jin Mu|Baoding traditional Chinese Medicine Co., Ltd. Registration number: 2013990000956 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20141216 Granted publication date: 20070328 Pledgee: Bank of Hebei, Limited by Share Ltd, Baoding branch Pledgor: Jin Mu| Baoding traditional Chinese Medicine Co., Ltd. Registration number: 2013990000956 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Mitutoyo road 071000 Hebei city of Baoding province No. 237 Patentee after: Baoding traditional Chinese medicine and pharmacy Limited by Share Ltd Address before: Mitutoyo road 071000 Hebei city of Baoding province No. 237 Patentee before: Baoding Chinese Medicine Preparing Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder |